130 related articles for article (PubMed ID: 16920824)
1. Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice.
Okazaki T; Terabe M; Catanzaro AT; Pendleton CD; Yarchoan R; Berzofsky JA
J Virol; 2006 Nov; 80(21):10645-51. PubMed ID: 16920824
[TBL] [Abstract][Full Text] [Related]
2. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen.
Okazaki T; Pendleton CD; Lemonnier F; Berzofsky JA
J Immunol; 2003 Sep; 171(5):2548-55. PubMed ID: 12928405
[TBL] [Abstract][Full Text] [Related]
3. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes.
Schmitt M; Harrer E; Goldwich A; Bäuerle M; Graedner I; Kalden JR; Harrer T
AIDS; 2000 Apr; 14(6):653-8. PubMed ID: 10807188
[TBL] [Abstract][Full Text] [Related]
4. Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections.
Kuse N; Rahman MA; Murakoshi H; Tran GV; Chikata T; Koyanagi M; Nguyen KV; Gatanaga H; Oka S; Takiguchi M
J Virol; 2015 Jul; 89(14):7363-72. PubMed ID: 25972553
[TBL] [Abstract][Full Text] [Related]
5. Reverse transcriptase-based DNA vaccines against drug-resistant HIV-1 tested in a mouse model.
Isaguliants MG; Zuber B; Boberg A; Sjöstrand D; Belikov SV; Rollman E; Zuber AK; Rechinsky VO; Rytting AS; Källander CF; Hinkula J; Kochetkov SN; Liu M; Wahren B
Vaccine; 2004 Apr; 22(13-14):1810-9. PubMed ID: 15068865
[TBL] [Abstract][Full Text] [Related]
6. Recognition patterns of HLA-A2-restricted human immunodeficiency virus-1-specific cytotoxic T-lymphocytes in a cohort of HIV-1-infected individuals.
Schmitt-Haendle M; Bachmann O; Harrer E; Schmidt B; Bäuerle M; Harrer T
Viral Immunol; 2005; 18(4):627-36. PubMed ID: 16359229
[TBL] [Abstract][Full Text] [Related]
7. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
Gao HQ; Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Mol Biol; 2000 Jul; 300(2):403-18. PubMed ID: 10873473
[TBL] [Abstract][Full Text] [Related]
8. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
[TBL] [Abstract][Full Text] [Related]
9. Naturally selected rilpivirine-resistant HIV-1 variants by host cellular immunity.
Gatanaga H; Murakoshi H; Hachiya A; Hayashida T; Chikata T; Ode H; Tsuchiya K; Sugiura W; Takiguchi M; Oka S
Clin Infect Dis; 2013 Oct; 57(7):1051-5. PubMed ID: 23797286
[TBL] [Abstract][Full Text] [Related]
10. Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses.
Klein MR; van der Burg SH; Hovenkamp E; Holwerda AM; Drijfhout JW; Melief CJ; Miedema F
J Gen Virol; 1998 Sep; 79 ( Pt 9)():2191-201. PubMed ID: 9747728
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance.
Loemba H; Brenner B; Parniak MA; Ma'ayan S; Spira B; Moisi D; Oliveira M; Detorio M; Essex M; Wainberg MA
Antiviral Res; 2002 Nov; 56(2):129-42. PubMed ID: 12367719
[TBL] [Abstract][Full Text] [Related]
13. Creating HIV-1 reverse transcriptase cytotoxic T lymphocyte target structures by HLA-A2 heavy chain modifications.
Dela Cruz CS; Tan R; Rowland-Jones SL; Barber BH
Int Immunol; 2000 Sep; 12(9):1293-302. PubMed ID: 10967024
[TBL] [Abstract][Full Text] [Related]
14. Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.
Aquaro S; Svicher V; Ceccherini-Silberstein F; Cenci A; Marcuccilli F; Giannella S; Marcon L; Caliò R; Balzarini J; Perno CF
J Antimicrob Chemother; 2005 Jun; 55(6):872-8. PubMed ID: 15845785
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice.
Abdel-Motal UM; Friedline R; Poligone B; Pogue-Caley RR; Frelinger JA; Tisch R
Clin Immunol; 2001 Oct; 101(1):51-8. PubMed ID: 11580226
[TBL] [Abstract][Full Text] [Related]
16. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response.
Miller V; Stark T; Loeliger AE; Lange JM
HIV Med; 2002 Apr; 3(2):135-45. PubMed ID: 12010361
[TBL] [Abstract][Full Text] [Related]
17. Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
Andreatta KN; Goodman DD; Miller MD; White KL
Antimicrob Agents Chemother; 2015; 59(6):3441-9. PubMed ID: 25824231
[TBL] [Abstract][Full Text] [Related]
18. A truncated plasmid-encoded HIV-1 reverse transcriptase displays strong immunogenicity.
Hallengärd D; Wahren B; Bråve A
Viral Immunol; 2013 Apr; 26(2):163-6. PubMed ID: 23573980
[TBL] [Abstract][Full Text] [Related]
19. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor.
Harrer E; Harrer T; Barbosa P; Feinberg M; Johnson RP; Buchbinder S; Walker BD
J Infect Dis; 1996 Feb; 173(2):476-9. PubMed ID: 8568316
[TBL] [Abstract][Full Text] [Related]
20. An integrated molecular dynamics, principal component analysis and residue interaction network approach reveals the impact of M184V mutation on HIV reverse transcriptase resistance to lamivudine.
Bhakat S; Martin AJ; Soliman ME
Mol Biosyst; 2014 Aug; 10(8):2215-28. PubMed ID: 24931725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
